SpaceX Crew‑12 completes 237‑day mission, returns to Earth

NASA and SpaceX astronauts aboard the Crew‑12 capsule landed safely at Cape Canaveral after a 237‑day stay in orbit, having travelled more than 100 million miles and completed over 3 792 orbits around the planet.

The crew’s return follows a mission that delivered a range of experiments aimed at paving the way for future journeys to the Moon and Mars. They carried out research on human physiology, materials science and deep‑space life‑support systems, with several studies set to influence both spaceflight and Earth‑based medicine.

During the flight, the astronauts achieved record‑setting spacewalks, adding new data on the challenges of extravehicular activity at extended durations. The spacewalks also tested a next‑generation suit designed for longer missions.

One experiment focused on the effects of microgravity on bone density and muscle mass, employing advanced imaging techniques that could help refine counter‑measures for long‑term crews. Another study examined the behaviour of blood flow in the absence of gravity, offering insights that may improve treatments for cardiovascular conditions on Earth.

In a materials science test, the crew exposed a polymer composite to the harsh space environment for six months, collecting data to inform the construction of habitats that can withstand micrometeoroid impacts and extreme temperature swings.

SpaceX’s Crew‑12 also delivered a set of new habitat modules to the International Space Station (ISS). The modules, built in partnership with a consortium of European and Asian aerospace firms, were integrated into the station’s habitat and will serve as test beds for future lunar and Martian habitats.

According to NASA, the mission’s research portfolio includes studies on radiation shielding, artificial gravity simulations and the use of 3D‑printed components in space. These investigations are intended to reduce risk for astronauts on longer missions beyond low Earth orbit.

The crew’s return marks the end of the longest continuous human presence in orbit since the early 2000s. The experience is expected to shape design choices for NASA’s Artemis lunar programme and the planned crewed Mars missions.

“The data gathered will directly influence how we plan for crew health and habitat design on the Moon and Mars,” said a NASA spokesperson. “It’s a vital step toward making those missions safe and sustainable.”

The Crew‑12 capsule was launched on 10 October 2025 on a Falcon 9 rocket from Cape Canaveral, and it docked with the ISS after a four‑day transit. The crew departed the station on 1 October 2026, returning to Earth two days later.

As the space community prepares for the next phase of human space exploration, the findings from this mission will be scrutinised by scientists and engineers worldwide, potentially reshaping the design of spacecraft and life‑support systems for the decades ahead.

NASA will review the mission’s data in the coming weeks, and the agency has already begun drafting plans to apply the insights to upcoming Artemis and Mars crewed launches.

Implications for future lunar and Martian missions

Long‑duration missions require robust solutions for health, habitat durability and resource utilisation. The Crew‑12 experiments are directly relevant to these challenges.

Studies on bone loss and muscle atrophy will inform counter‑measure protocols for crews on the Moon, where reduced gravity could accelerate tissue loss. The new materials tested for micrometeoroid resistance will aid in designing habitats that can survive the micrometeoroid‑rich environment of the lunar surface.

Artificial gravity experiments conducted on the ISS are a key element of the proposed lunar surface habitat design, which envisages rotating habitats to provide partial gravity for crew health.

On Mars, where radiation exposure is a major concern, the new shielding materials and radiation monitoring techniques could be adapted for surface habitats and spacecraft.

Medical advances with Earth‑wide benefits

Research into cardiovascular responses to microgravity could translate into new therapies for patients with heart failure or orthostatic hypotension. The imaging techniques used to monitor bone density might improve early detection of osteoporosis.

Moreover, the 3D‑printing experiments demonstrate that complex components can be manufactured on orbit, offering a potential new paradigm for medical device fabrication and rapid response to equipment failures.

Scientists are already exploring how the data from the mission could improve drug delivery systems and tissue engineering protocols on Earth.

With the successful conclusion of the Crew‑12 mission, NASA and SpaceX have provided a wealth of data that will shape the next generation of human spaceflight and medical innovation.

As the agency reviews the results, the broader scientific community will assess how the mission’s findings can be incorporated into future projects aimed at establishing a sustainable human presence beyond Earth.

Looking ahead

NASA’s Artemis programme aims to land astronauts on the Moon’s south pole by the end of the decade, and the agency has identified the Crew‑12 data as a cornerstone for the mission’s design. Meanwhile, plans for crewed missions to Mars are scheduled for the early 2030s, with the technology developed during this mission expected to play a key role.

In the meantime, the space community will continue to monitor the health data collected during the 237‑day stay, seeking to refine counter‑measures and support systems for future crews.

For now, the astronauts and the teams that supported them can take a moment to celebrate a milestone that brings humanity a step closer to living beyond low Earth orbit.